common stock, $.0001 par value
- Symbol
- SIGA
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
SIGANASDAQEQUITYCurrent
Item 2.02 Results of Operations and Financial Condition. On May 7, 2026, SIGA Technologies, Inc. (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the three months ended March 31, 2026.…
SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on smallpox, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. For more information about SIGA, visit www.siga.com.
SIGA TECHNOLOGIES, INC. · 8-K · Filed 2026-05-07
EX-99.1 2 ef20072552_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Press Release Press Release SIGA Reports Financial Results for Three Months Ended March 31, 2026 and Provides Business Update On Track to Deliver $13 Million of Oral TPOXX to an International Customer in Second Quarter Expect to Deliver $26 Million of IV TPOXX to the U.S. Government Strategic National Stockpile by End of the Third Quarter Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, May 7, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2026. “Consistent with our long-term strategy, we expect to deliver more than $35 million of oral and IV TPOXX to a combination of the U.S. Government and an international customer across the second and third quarters of 2026," stated Diem Nguyen, Chief Executive Officer. "Our focus remains on securing new procurement contracts and orders that can drive our business going forward, building upon our long track record as a successful partner to the U.S. and international governments.” Summary Financial Results ($ in m…
Open exhibit ↗